Prague Med. Rep. 2017, 118, 105-109

https://doi.org/10.14712/23362936.2017.11

Meropenem-induced Valproic Acid Elimination: A Case Report of Clinically Relevant Drug Interaction

Martin Šíma1, Jan Hartinger1, Jan Rulíšek2, Robert Šachl1,2, Ondřej Slanař1

1Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
2Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

Received April 24, 2017
Accepted August 28, 2017

References

1. Bentué-Ferrer, D., Tribut, O., Verdier, M. C., Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique (2010) Therapeutic drug monitoring of valproate. Therapie 65, 233–240. (in French). <https://doi.org/10.2515/therapie/2010029>
2. Cannon, J. P., Lee, T. A., Clark, N. M., Setlak, P., Grim, S. A. (2014) The risk of seizures among the carbapenems: a meta-analysis. J. Antimicrob. Chemother. 69, 2043–2055. <https://doi.org/10.1093/jac/dku111>
3. Clause, D., Decleire, P. Y., Vanbinst, R., Soyer, A., Hantson, P. (2005) Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Med. 31, 1293–1294. <https://doi.org/10.1007/s00134-005-2695-0>
4. Fudio, S., Carcas, A., Piñana, E., Ortega, R. (2006) Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J. Clin. Pharm. Ther. 31, 393–396. <https://doi.org/10.1111/j.1365-2710.2006.00743.x>
5. Ghodke-Puranik, Y., Thorn, C. F., Lamba, J. K., Leeder, J. S., Song, W., Birnbaum, A. K., Altman, R. B., Klein, T. E. (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics 23, 236–241. <https://doi.org/10.1097/FPC.0b013e32835ea0b2> <PubMed>
6. Loh, G. W., Mabasa, V. H., Ensom, M. H. (2010) Therapeutic drug monitoring in the neurocritical care unit. Curr. Opin. Crit. Care 16, 128–135. <https://doi.org/10.1097/MCC.0b013e3283374e3c>
7. Nacarkucuk, E., Saglam, H., Okan, M. (2004) Meropenem decreases serum level of valproic acid. Pediatr. Neurol. 31, 232–234. <https://doi.org/10.1016/j.pediatrneurol.2004.03.014>
8. Nakajima, Y., Mizobuchi, M., Nakamura, M., Takagi, H., Inagaki, H., Kominami, G., Koike, M., Yamaguchi, T. (2004) Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab. Dispos. 32, 1383–1391. <https://doi.org/10.1124/dmd.104.000661>
9. Peterson, G. M., Naunton, M. (2005) Valproate: a simple chemical with so much to offer. J. Clin. Pharm. Ther. 30, 417–421. <https://doi.org/10.1111/j.1365-2710.2005.00671.x>
10. Suntimaleeworakul, W., Patharachayakul, S., Chusri, S. (2012) Drug interaction between valproic acid and meropenem: a case report. J. Med. Assoc. Thai. 95, 293–295.
11. Suzuki, E., Yamamura, N., Ogura, Y., Nakai, D., Kubota, K., Kobayashi, N., Miura, S., Okazaki, O. (2010) Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab. Dispos. 38, 1538–1544. <https://doi.org/10.1124/dmd.110.032938>
12. Suzuki, E., Nakai, D., Yamamura, N., Kobayashi, N., Okazaki, O., Izumi, T. (2011) Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid. Xenobiotica 41, 958–963. <https://doi.org/10.3109/00498254.2011.596582>
13. Tomson, T., Dahl, M. L., Kimland, E. (2007) Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst. Rev. 2, CD002216.
14. Wen, Z. P., Fan, S. S., Du, C., Yin, T., Zhou, B. T., Peng, Z. F., Xie, Y. Y., Zhang, W., Chen, Y., Xiao, J., Chen, X. P. (2017) Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J. Clin. Pharm. Ther. 42, 221–227. <https://doi.org/10.1111/jcpt.12501>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive